Publication|Articles|September 13, 2024
- Applied Clinical Trials-09-01-2024
- Volume 33
- Issue 9
Applied Clinical Trials September 2024 Issue (PDF)
Click the title above for a link to open the Applied Clinical Trials September 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 2 years ago
Aligning Technology and Oversightalmost 2 years ago
A New Regulatory Road in Clinical Trials: Digital Twinsalmost 2 years ago
Bridging Patient Support Gaps While Navigating Global Regulationsalmost 2 years ago
Regulatory CMC: Enhancing Biologics Developmentalmost 2 years ago
In Focus: Top Takeaways from FDA Final Guidance on Real-World Evidencealmost 2 years ago
Driving Inclusion in Clinical Trials: Less Talk, More Trustalmost 2 years ago
Risk Planning: A Review of Industry Trendsabout 2 years ago
An Overview of FDA Diversity-Related Documents for Clinical TrialsAdvertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Selective Safety Data and Visit Reduction, Protocol Design Execution Gaps, and China Trial Security Investigation
2
NEJM Retracts Tavneos Trial Paper as FDA, EMA Both Move to Pull Amgen Drug From Market
3
ACT Brief: Tavneos Trial Integrity Issues, Selective Safety Data Regulatory Pathways, and FDA PreCheck Program Launch
4
Protocol Design Doesn't Fail in the Protocol, It Fails in Transition to Trial
5